Which single feature best distinguishes localized prostate cancer (T1–T2, N0, M0) from locally advanced prostate cancer (T3–T4 or N1)?

Explanation

## Distinguishing Localized from Locally Advanced Prostate Cancer ### TNM Staging Framework The **TNM classification** is the gold standard for prostate cancer staging and prognosis. The critical boundary between localized (T1–T2) and locally advanced (T3–T4) disease is the **presence or absence of extraprostatic extension (EPE) and/or seminal vesicle invasion (SVI)**. ### Key Anatomical Distinction **Key Point:** T3a disease is defined by **microscopic or macroscopic EPE beyond the prostatic capsule**. T3b includes **seminal vesicle invasion**. T4 involves invasion of bladder neck, external sphincter, or rectum. These features are **pathognomonic for locally advanced disease** and fundamentally alter staging, prognosis, and treatment strategy. ### Why EPE/SVI is the Best Discriminator | Feature | Localized (T1–T2) | Locally Advanced (T3–T4/N1) | |---------|-------------------|-----------------------------| | **Extraprostatic extension** | Absent | Present (T3a) | | **Seminal vesicle invasion** | Absent | Present (T3b) | | **Regional lymph node involvement** | N0 | N1 | | **Capsular integrity** | Intact | Breached | | **PSA level** | Highly variable (can be low or high) | Often elevated but overlaps | | **Gleason score** | Can be ≥8 in localized disease | Often ≥8 but not diagnostic | **Clinical Pearl:** EPE and SVI are **imaging and pathology findings**, not biochemical markers. They directly define the T-stage boundary and are **mandatory** for accurate TNM assignment. PSA, Gleason, and age are **prognostic factors** but do not define anatomic extent. ### Why Other Options Fail - **PSA > 20 ng/mL:** Overlaps significantly between localized and advanced disease; not a staging criterion. - **Gleason ≥ 8:** A **prognostic factor** but found in both localized and advanced cancers; does not define T-stage. - **Age > 70 years:** A demographic variable, not a staging or anatomic discriminator. **High-Yield:** On imaging (MRI) or final pathology, **EPE/SVI is the single most important finding that upgrades a patient from T2 to T3 stage**. This directly impacts treatment (surgery vs. radiotherapy + ADT vs. palliative care). [cite:Harrison 21e Ch 97]